Therapy for mixed dyslipidaemia through ANGPTL3 inhibition - ASCVD & Lipidology Knowledge Hub

This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Confirm

  • Share

  • Stay up to date
  • Home
  • Topics
    • Cardiovascular Diseases and Conditions
      • Acute Coronary Syndrome
      • Atherosclerosis
      • Coronary artery disease
      • CVD
      • ASCVD
      • Myocardial Infarction
    • Lipid Metabolism and Disorders
      • Lipids
        • PUFA
          • Eicosanoids
      • Cholesterol
        • High-density lipoprotein
        • Low-density lipoprotein
        • Low-density Lipoprotein Cholesterol
        • Lipoprotein (a)
        • Apolipoprotein B
        • Hypercholesterolemia
        • Hyperlipidemia
        • Dyslipidemia
        • Familial hypercholesterolemia
      • Triglycerides
      • Cholesterol synthesis
      • Cholesterol absorption
    • Medications and Therapies
      • Therapy
      • Lipid lowering therapy
        • Statin
          • High-intensity statin
        • PCSK9
          • Alirocumab
          • Evolocumab
        • Bempedoic acid
        • Icosapent Ethyl
        • Inclisiran
        • Obicetrapib
        • Zerlasiran
      • Combination therapy
      • Aspirin
      • Immunotherapy
      • Short interfering RNA (siRNA)
      • Diabetes
    • Risk Factors and Prevention
      • CVD Risk Factor
      • Primary prevention
      • Prevention
      • Risk assessment
      • Women
      • Inflammation
      • Calcium Scoring
    • Clinical Research and Guidelines
      • Clinical Trial
      • Trials
      • Guidelines
      • Consensus statement
      • Registry
      • GOULD
    • Other Related Topics
      • Congresses
      • Global health
      • Vaccination
        • Influenza
      • Non-adherence
      • Pediatric Population
      • Plaques
      • Obesity
    • Molecular and Genetic Factors
      • ANGPTL3
  • Webinars/Videos
  • Infographics
  • Articles
  • Case Studies
  • Forum
  • Faculty
  • Unblocked
  • Stay up to date

Articles

Therapy for mixed dyslipidaemia through ANGPTL3 inhibition

Santos RD

Journal: 

Lancet

First published: May 3, 2025  DOI: 10.1016/S0140-6736(25)00613-0

How would you rate this content?

  • © John Wiley & Sons, Ltd. All rights reserved.
  • Privacy Policy
  • Terms of use
  • Stay up to date
  • Cookie Preferences
  • This Knowledge Hub is supported by Novartis.
Clinical Cardiology